A. Hilgeroth

发表

Novel CDK inhibition profiles of structurally varied 1-aza-9-oxafluorenes.

L. Meijer, F. Totzke, B. Voigt, 2005, Bioorganic & medicinal chemistry letters.

Discovery of pyridine-2-ones as novel class of multidrug resistance (MDR) modulators: first structure-activity relationships.

A. Hilgeroth, Sören Krawczyk, M. Otto, 2011, Bioorganic & medicinal chemistry.

Dimeric 4-Aryl-1,4-dihydropyridines: development of a third class of nonpeptidic HIV-1 protease inhibitors.

A. Hilgeroth, 2002, Mini reviews in medicinal chemistry.

Structure-activity relationships of first bishydroxymethyl-substituted cage dimeric 4-aryl-1,4-dihydropyridines as HIV-1 protease inhibitors.

H. Lilie, A. Hilgeroth, 2003, European journal of medicinal chemistry.

Dually Acting Nonclassical 1,4-Dihydropyridines Promote the Anti-Tuberculosis (Tb) Activities of Clofazimine

J. Molnár, N. Reiling, A. Hilgeroth, 2019, Molecules.

Novel structure-activity relationships and selectivity profiling of cage dimeric 1,4-dihydropyridines as multidrug resistance (MDR) modulators.

A. Hilgeroth, H. Lage, C. Coburger, 2010, Bioorganic & medicinal chemistry.

Recent developments of protein kinase inhibitors as potential AD therapeutics

A. Hilgeroth, V. Tell, 2013, Front. Cell. Neurosci..

Novel Symmetrical Cage Compounds as Inhibitors of the Symmetrical MRP4-Efflux Pump for Anticancer Therapy

A. Hilgeroth, P. Werner, C. Ritter, 2021, International journal of molecular sciences.

Novel aspects in structure–activity relationships of profiled 1-aza-9-oxafluorenes as inhibitors of Alzheimer's disease-relevant kinases cdk1, cdk5 and gsk3β

F. Totzke, W. Sippl, K. Wichapong, 2012 .

Multitargeted drug development: Discovery and profiling of dihydroxy substituted 1-aza-9-oxafluorenes as lead compounds targeting Alzheimer disease relevant kinases.

F. Totzke, C. Schächtele, A. Hilgeroth, 2012, Bioorganic & medicinal chemistry letters.

Novel CDK Inhibition Profiles of Structurally Varied 1-Aza-9-oxafluorenes.

L. Meijer, F. Totzke, B. Voigt, 2005 .

Regioselective Formation of Novel Functionalized 1-Aza-9-oxafluorenes

A. Hilgeroth, U. Baumeister, K. Brachwitz, 2001 .

Synthesis and first biological evaluation of 1-aza-9-oxafluorenes as novel lead structures for the development of small-sized cytostatics.

A. Hilgeroth, K. Brachwitz, 2002, Bioorganic & medicinal chemistry letters.

Multidrug resistance reversal properties and cytotoxic evaluation of representatives of a novel class of HIV‐1 protease inhibitors

A. Hilgeroth, A. Langner, H. Lage, 2010, The Journal of pharmacy and pharmacology.

Novel Tetraindoles and Unexpected Cycloalkane Indoles from the Reaction of Indoles and Aliphatic Dialdehydes

A. Hilgeroth, F. Heinemann, M. El-Sayed, 2017 .

Discovery and selectivity-profiling of 4-benzylamino 1-aza-9-oxafluorene derivatives as lead structures for IGF-1R inhibitors.

F. Totzke, W. Sippl, C. Schächtele, 2010, Bioorganic & medicinal chemistry letters.

Antitumor activity of terpenoids against classical and atypical multidrug resistant cancer cells.

A. Hilgeroth, H. Lage, N. Duarte, 2010, Phytomedicine : international journal of phytotherapy and phytopharmacology.

Synergistic interaction between p-glycoprotein modulators and epirubicine on resistant cancer cells.

Maria-José U. Ferreira, J. Molnár, A. Hilgeroth, 2008, Bioorganic & medicinal chemistry.

Novel inhibitors of the methicillin-resistant Staphylococcus aureus (MRSA)-pyruvate kinase

M. Lalk, R. Zoraghi, N. Reiner, 2016, Journal of enzyme inhibition and medicinal chemistry.

Discovery of substituted 1,4-dihydroquinolines as novel class of ABCB1 modulators.

A. Hilgeroth, H. Lage, Sören Krawczyk, 2015, Bioorganic & medicinal chemistry.

Novel non-substrate modulators of the transmembrane efflux pump P-glycoprotein (ABCB1)

A. Hilgeroth, C. Kloft, Sören Krawczyk, 2015 .

P‐Glycoprotein Effects of Cyclic Urea HIV Protease Inhibitor DMP 323 in Competitional Absorption Studies

A. Hilgeroth, J. Molnár, N. Gyémánt, 2006, Archiv der Pharmazie.

Discovery of novel N-phenyl 1,4-dihydropyridines with a dual mode of antimycobacterial activity.

N. Reiling, A. Hilgeroth, Fabian Lentz, 2016, Bioorganic & medicinal chemistry letters.

Novel Effective Small-Molecule Antibacterials against Enterococcus Strains

M. Lalk, K. Ohlsen, A. Hilgeroth, 2017, Molecules.

The interaction between resistance modifiers such as pyrido[3,2-g]quinoline, aza-oxafluorene and pregnane derivatives with DNA, plasmid DNA and tRNA.

J. Molnár, A. Hilgeroth, G. Spengler, 2005, European journal of medicinal chemistry.

Novel Small-molecule Antibacterials against Gram-positive Pathogens of Staphylococcus and Enterococcus Species

M. Lalk, K. Ohlsen, A. Hilgeroth, 2019, Antibiotics.

FIRST OXIDIZED TETRAINDOLES WITH ANTIMICROBIAL EVALUATION AND STRUCTURE ACTIVITY RELATIONSHIP

A. Hilgeroth, H. Awad, K. Ahmed, 2022 .

Development of small-molecule P-gp inhibitors of the N-benzyl 1,4-dihydropyridine type: novel aspects in SAR and bioanalytical evaluation of multidrug resistance (MDR) reversal properties.

A. Hilgeroth, A. Langner, H. Lage, 2013, Bioorganic & medicinal chemistry.

Novel effective small-molecule inhibitors of protein kinases related to tau pathology in Alzheimer's disease.

Fady N. Baselious, W. Sippl, V. Kryštof, 2022, Future medicinal chemistry.

Synthesis of β-Nitroamines via Classical Mannich and Aza-Henry Reactions

A. Hilgeroth, M. El-Sayed, Kazem Mahmoud, 2013 .

Discovery of a novel class of small-molecule antibacterial agents against Staphylococcus aureus.

A. Hilgeroth, G. Spengler, J. Molnár, 2021, Future medicinal chemistry.

Synthesis and biological evaluation of the first N-alkyl cage dimeric 4-aryl-1,4-dihydropyridines as novel nonpeptidic HIV-1 protease inhibitors.

A. Hilgeroth, M. Wiese, A. Billich, 1999, Journal of medicinal chemistry.

Novel Protein Kinase Inhibitors Related to Tau Pathology Modulate Tau Protein-Self Interaction Using a Luciferase Complementation Assay

F. Totzke, W. Sippl, C. Schächtele, 2018, Molecules.

Discovery of dually acting small-molecule inhibitors of cancer-resistance relevant receptor tyrosine kinases EGFR and IGF-1R

F. Totzke, W. Sippl, C. Schächtele, 2016 .

Synthesis of Novel Indolo‐Spirocyclic Compounds

A. Hilgeroth, I. Fakhr, M. El-Sayed, 2016 .

Structure—Activity Relationships of First Bishydroxymethyl-Substituted Cage Dimeric 4-Aryl-1,4-dihydropyridines as HIV-1 Protease Inhibitors.

H. Lilie, A. Hilgeroth, 2003 .

Recent advances in the development of multi-kinase inhibitors.

Martin Krug, Andreas Hilgeroth, A. Hilgeroth, 2008, Mini reviews in medicinal chemistry.

Discovery of Novel Symmetrical 1,4-Dihydropyridines as Inhibitors of Multidrug-Resistant Protein (MRP4) Efflux Pump for Anticancer Therapy

A. Hilgeroth, C. Ritter, David Kreutzer, 2020, Molecules.

Biological evaluation of bishydroxymethyl-substituted cage dimeric 1,4-dihydropyridines as a novel class of p-glycoprotein modulating agents in cancer cells.

A. Hilgeroth, J. Molnár, Martin Richter, 2006, Journal of medicinal chemistry.

Formation of novel photodimers from 4-aryl-1,4-dihydropyridines.

A. Hilgeroth, U. Baumeister, 2001, Chemistry.

Synthesis, cytostatic evaluation and structure activity relationships of novel bis-indolylmethanes and their corresponding tetrahydroindolocarbazoles.

A. Hilgeroth, K. Ahmed, Mardia T. El Sayed, 2015, European journal of medicinal chemistry.

Glacial acetic acid as an efficient catalyst for simple synthesis of dindolylmethanes

A. Hilgeroth, M. El-Sayed, Kazem Mahmoud, 2014 .

Synthesis and biological evaluation of first N-alkyl syn dimeric 4-aryl-1,4-dihydropyridines as competitive HIV-1 protease inhibitors.

H. Lilie, A. Hilgeroth, A. Billich, 2001, European journal of medicinal chemistry.

Evaluation of the first cytostatically active 1-aza-9-oxafluorenes as novel selective CDK1 inhibitors with P-glycoprotein modulating properties.

L. Meijer, B. Voigt, O. Lozach, 2003, Journal of medicinal chemistry.

Using molecular symmetry to form new drugs: hydroxymethyl-substituted 3,9-diazatetraasteranes as the first class of symmetric MDR modulators.

A. Hilgeroth, J. Molnár, E. De Clercq, 2002, Angewandte Chemie.

Discovery of bisindolyl-substituted cycloalkane-anellated indoles as novel class of antibacterial agents against S. aureus and MRSA.

K. Ohlsen, A. Hilgeroth, S. Suzen, 2016, Bioorganic & medicinal chemistry letters.

First Insight into the Symmetry and Flexibility of Membrane Efflux Pump P‐Glycoprotein by Novel Bifunctional Modulators

A. Hilgeroth, J. Molnár, J. Wollmann, 2005, Chembiochem : a European journal of chemical biology.

Novel solid-state synthesis of dimeric 4-aryl-1,4-dihydropyridines

A. Hilgeroth, F. Heinemann, 1998 .

Solution‐Dimerization of 4‐Aryl‐1,4‐dihydropyridines

A. Hilgeroth, F. Heinemann, U. Baumeister, 2000 .

Cage Dimeric N‐Acyl‐ and N‐Acyloxy‐4‐aryl‐1,4‐dihydropyridines as First Representatives of a Novel Class of HIV‐1 Protease Inhibitors

A. Hilgeroth, A. Billich, 1999, Archiv der Pharmazie.

Novel Solid‐State Synthesis of Polyfunctionalized 3,9‐Diazatetraasteranes

A. Hilgeroth, F. Heinemann, U. Baumeister, 1998 .

Topochemical characterization of photostable 4-hydroxyaryl-1,4-dihydropyridines by X-ray crystal structure analysis

A. Hilgeroth, U. Baumeister, J. Wollmann, 2005 .

Solid‐state formation of centrosymmetric cage dimeric 4‐aryl‐1,4‐dihydropyridines via non‐symmetric syn‐dimers studied by 13C cross‐polarization magic angle spinning NMR spectroscopy

A. Hilgeroth, U. Baumeister, G. Hempel, 1999 .

Solid-state photodimerization of 4-aryl-1,4-dihydropyridines studied by 13C CPMAS NMR spectroscopy.

A. Hilgeroth, U. Baumeister, G. Hempel, 1999, Solid state nuclear magnetic resonance.

Novel Solid-State Synthesis of Polyfunctionalized 3,9-Diazatetraasteranes.

A. Hilgeroth, F. Heinemann, U. Baumeister, 1998 .

Bioanalysis of Syn Dimeric HIV‐1 Protease Inhibitor N‐Benzyl 4‐Aryl‐1,4‐dihydropyridine H19: Metabolic and Cytotoxic Properties in Hep G2 Cells

A. Hilgeroth, A. Langner, 2000, Archiv der Pharmazie.

Cage Dimeric N-Acyl- and N-Acyloxy-4-aryl-1,4-dihydropyridines as First Representatives of a Novel Class of HIV-1 Protease Inhibitors.

A. Hilgeroth, A. Billich, 2000 .

The impact of the induction of multidrug resistance transporters in therapies by used drugs: recent studies.

A. Hilgeroth, C. Coburger, M. Hemmer, 2012, Mini reviews in medicinal chemistry.

Novel inhibitors of breast cancer relevant kinases Brk and HER2

F. Totzke, W. Sippl, C. Schächtele, 2014 .

Discovery of 4-anilino α-carbolines as novel Brk inhibitors.

F. Totzke, W. Sippl, C. Schächtele, 2014, Bioorganic & medicinal chemistry letters.

Discovery of 4‐Benzylamino‐Substituted α‐Carbolines as a Novel Class of Receptor Tyrosine Kinase Inhibitors

Wolfgang Sippl, Martin Krug, Andreas Hilgeroth, 2011, ChemMedChem.

Impact of Novel MDR Modulators on Human Cancer Cells: Reversal Activities and Induction Studies

A. Hilgeroth, H. Lage, C. Coburger, 2008, Pharmaceutical Research.

First biological evaluation of developed 3-benzyloxyfluorenes as novel class of MDR modulators.

B. Voigt, A. Hilgeroth, M. Krug, 2010, European journal of medicinal chemistry.

Discovery of novel dual inhibitors of receptor tyrosine kinases EGFR and PDGFR-β related to anticancer drug resistance

F. Totzke, W. Sippl, C. Schächtele, 2017, Journal of enzyme inhibition and medicinal chemistry.

Discovery of novel dual inhibitors of receptor tyrosine kinases EGFR and IGF-1R

F. Totzke, W. Sippl, C. Schächtele, 2017, Journal of enzyme inhibition and medicinal chemistry.

Structure-activity relationships of novel N-acyloxy-1,4-dihydropyridines as P-glycoprotein inhibitors.

B. Voigt, A. Hilgeroth, C. Coburger, 2007, Bioorganic & medicinal chemistry.

Correlation of calculated molecular orbital energies of some phenothiazine compounds with MDR reversal properties.

B. Voigt, A. Hilgeroth, J. Molnár, 2006, European journal of medicinal chemistry.

Evaluation of substrate and inhibitor properties of a novel MDR modulator H17 towards transmembrane efflux pumps.

A. Hilgeroth, A. Langner, Martin Richter, 2009, European journal of medicinal chemistry.

Probing Novel 1‐Aza‐9‐oxafluorenes as Selective GSK‐3β Inhibitors

F. Totzke, B. Voigt, C. Schächtele, 2008, ChemMedChem.

Recent advances in the development of P-gp inhibitors.

A. Hilgeroth, C. Baumert, 2009, Anti-cancer agents in medicinal chemistry.

Novel Small-Molecule Hybrid-Antibacterial Agents against S. aureus and MRSA Strains

M. Lalk, K. Ohlsen, A. Hilgeroth, 2021, Molecules.

Antibacterial Evaluation of Novel Substituted Cycloheptaindoles in Staphylococcus and Enterococcus strains.

M. Lalk, K. Ohlsen, A. Hilgeroth, 2019, Medicinal chemistry (Shariqah (United Arab Emirates)).

Antistaphylococcal evaluation of indole–naphthalene hybrid analogs

M. Lalk, K. Ohlsen, A. Hilgeroth, 2019, Drug design, development and therapy.

Novel Effective Fluorinated Benzothiophene-Indole Hybrid Antibacterials against S. aureus and MRSA Strains

M. Lalk, K. Ohlsen, A. Hilgeroth, 2022, Pharmaceuticals.

Diazatruxenes from the Condensation Reaction of Indoles with Ninhydrin

A. Hilgeroth, L. Wessjohann, A. Porzel, 2017 .

Novel Insight into Inhibitor Binding of Highly Symmetric HIV‐1 Protease

W. Sippl, A. Hilgeroth, J. Wollmann, 2008, Chembiochem : a European journal of chemical biology.

Discovery of Novel Enhancers of Isoniazid Toxicity in Mycobacterium tuberculosis

J. Molnár, N. Reiling, A. Hilgeroth, 2018, Molecules.

Solid-state Synthesis of Novel 3,9-Diazatetraasteranes

A. Hilgeroth, 1997 .

Solid-State Synthesis of Novel 3,9-Diazatetraasteranes.

A. Hilgeroth, 1998 .

Novel insight in structure-activity relationship and bioanalysis of P-glycoprotein targeting highly potent tetrakishydroxymethyl substituted 3,9-diazatetraasteranes.

A. Hilgeroth, H. Lage, C. Coburger, 2008, Journal of medicinal chemistry.

Novel Nonsymmetrical 1,4-Dihydropyridines as Inhibitors of Nonsymmetrical MRP-Efflux Pumps for Anticancer Therapy

A. Hilgeroth, C. Ritter, David Kreutzer, 2020, Pharmaceuticals.

Discovery of novel substituted benzo-anellated 4-benzylamino pyrrolopyrimidines as dual EGFR and VEGFR2 inhibitors.

F. Totzke, W. Sippl, A. Hilgeroth, 2017, Bioorganic & medicinal chemistry letters.

Discovery and selectivity-profiling of 4-benzylamino 1-aza-9-oxafluorene derivatives as lead structures for IGF-1R inhibitors.

F. Totzke, W. Sippl, A. Hilgeroth, 2010, Bioorganic & medicinal chemistry letters.